The importance of NAT1 and NAT2 in the metabolism of drugs and in the activation of common environmental carcinogens has led to a plethora of molecular epidemiological studies that have shown associations of NAT gene polymorphisms with individual drug response and susceptibility to cancers linked to arylamine exposure [14-16]. The gene discussed is NAT2; the disease is cancer.